First-quarter ZILRETTA® net sales estimated to be approximately $24 .6 million 2021 full-year ZILRETTA net sales anticipated to be in the range of $120 million to $130 million and total operating expenses expected between $195 million to $205 million Company to hold conference call today at 4:30
BURLINGTON, Mass. , April 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham 20 th Annual Healthcare Conference.
BURLINGTON, Mass. , April 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 60,880 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogel Proof-of-concept trial will evaluate safety and tolerability of FX301 administered as a peripheral analgesic nerve block in patients undergoing bunionectomy; initial
BURLINGTON, Mass. , March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019 First patient treated in high dose cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201 in patients
BURLINGTON, Mass. , March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
BURLINGTON, Mass. , March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021 .
FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block FX301 may provide 3 to 5 days of non-opioid pain relief while preserving motor function following musculoskeletal surgery Proof of concept Phase
BURLINGTON, Mass. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42 nd Annual Raymond James Institutional Investors Conference .
